These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 29162429)

  • 1. Studies with psychedelic drugs in human volunteers.
    Sellers EM; Romach MK; Leiderman DB
    Neuropharmacology; 2018 Nov; 142():116-134. PubMed ID: 29162429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating the abuse potential of psychedelic drugs as part of the safety pharmacology assessment for medical use in humans.
    Heal DJ; Gosden J; Smith SL
    Neuropharmacology; 2018 Nov; 142():89-115. PubMed ID: 29427652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Psychedelics: Where we are now, why we got here, what we must do.
    Belouin SJ; Henningfield JE
    Neuropharmacology; 2018 Nov; 142():7-19. PubMed ID: 29476779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Psychiatry & the psychedelic drugs. Past, present & future.
    Rucker JJH; Iliff J; Nutt DJ
    Neuropharmacology; 2018 Nov; 142():200-218. PubMed ID: 29284138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Why MDMA therapy for alcohol use disorder? And why now?
    Sessa B
    Neuropharmacology; 2018 Nov; 142():83-88. PubMed ID: 29126911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A regulatory perspective on the evaluation of hallucinogen drugs for human use.
    Calderon SN; Hunt J; Klein M
    Neuropharmacology; 2018 Nov; 142():135-142. PubMed ID: 29180224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Some distorted thoughts about ketamine as a psychedelic and a novel hypothesis based on NMDA receptor-mediated synaptic plasticity.
    Ingram R; Kang H; Lightman S; Jane DE; Bortolotto ZA; Collingridge GL; Lodge D; Volianskis A
    Neuropharmacology; 2018 Nov; 142():30-40. PubMed ID: 29885421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dreams and Psychedelics: Neurophenomenological Comparison and Therapeutic Implications.
    Kraehenmann R
    Curr Neuropharmacol; 2017; 15(7):1032-1042. PubMed ID: 28625125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The renaissance in psychedelic research: What do preclinical models have to offer.
    Murnane KS
    Prog Brain Res; 2018; 242():25-67. PubMed ID: 30471682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Psilocybin--summary of knowledge and new perspectives.
    Tylš F; Páleníček T; Horáček J
    Eur Neuropsychopharmacol; 2014 Mar; 24(3):342-56. PubMed ID: 24444771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The neurobiology of psychedelic drugs: implications for the treatment of mood disorders.
    Vollenweider FX; Kometer M
    Nat Rev Neurosci; 2010 Sep; 11(9):642-51. PubMed ID: 20717121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TCB-2 [(7R)-3-bromo-2, 5-dimethoxy-bicyclo[4.2.0]octa-1,3,5-trien-7-yl]methanamine]: A hallucinogenic drug, a selective 5-HT
    Di Giovanni G; De Deurwaerdère P
    Neuropharmacology; 2018 Nov; 142():20-29. PubMed ID: 28987938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A sub-set of psychoactive effects may be critical to the behavioral impact of ketamine on cocaine use disorder: Results from a randomized, controlled laboratory study.
    Dakwar E; Nunes EV; Hart CL; Hu MC; Foltin RW; Levin FR
    Neuropharmacology; 2018 Nov; 142():270-276. PubMed ID: 29309770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peak experiences and the afterglow phenomenon: when and how do therapeutic effects of hallucinogens depend on psychedelic experiences?
    Majić T; Schmidt TT; Gallinat J
    J Psychopharmacol; 2015 Mar; 29(3):241-53. PubMed ID: 25670401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Embedding existential psychology within psychedelic science: reduced death anxiety as a mediator of the therapeutic effects of psychedelics.
    Moreton SG; Szalla L; Menzies RE; Arena AF
    Psychopharmacology (Berl); 2020 Jan; 237(1):21-32. PubMed ID: 31784805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Psychedelics as an emerging novel intervention in the treatment of substance use disorder: a review.
    DiVito AJ; Leger RF
    Mol Biol Rep; 2020 Dec; 47(12):9791-9799. PubMed ID: 33231817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Psychedelics and quasi-psychedelics in the light of contemporary research: medical cannabis, MDMA, salvinorin A, ibogaine and ayahuasca].
    Szabó A; Kazai A; Frecska E; Brys Z
    Neuropsychopharmacol Hung; 2015 Sep; 17(3):120-8. PubMed ID: 26485742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reviewing the Potential of Psychedelics for the Treatment of PTSD.
    Krediet E; Bostoen T; Breeksema J; van Schagen A; Passie T; Vermetten E
    Int J Neuropsychopharmacol; 2020 Jun; 23(6):385-400. PubMed ID: 32170326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The entropic brain - revisited.
    Carhart-Harris RL
    Neuropharmacology; 2018 Nov; 142():167-178. PubMed ID: 29548884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular targets of psychedelic-induced plasticity.
    Jaster AM; de la Fuente Revenga M; González-Maeso J
    J Neurochem; 2022 Jul; 162(1):80-88. PubMed ID: 34741320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.